Key result
RBM20 variants linked to a severe cardiomyopathy spectrum with ~33% progressing to SCD or Htx.
Why the study?
The prevalence of RBM20 variants across proposed phenotypes according to the recent 2023 cardiomyopathy classification remains uncertain.
Cohort (n=14)
RBM20-related cardiomyopathy presents a broad phenotypic spectrum ranging from preserved ejection fraction with arrhythmias to end-stage heart failure, typically featuring normal or short PR intervals and narrow QRS complexes.
May support RBM20 testing in DCM with normal PR/QRS; leaves open management implications pending larger prospective validation.
Background The RBM20 gene encodes a protein involved in RNA splicing regulation. First linked to cardiomyopathy in 2009, its prevalence according to the recent 2023 cardiomyopathy classification, in each proposed phenotype remains uncertain. Purpose To describe the phenotypic profile of carriers of pathogenic/likely pathogenic RBM20 variants. Methods This ambispective, observational cohort study in patients with pathogenic/likely pathogenic RBM20 variants identified through genetic testing for structural heart disease or high-risk arrhythmogenic phenotypes (aborted sudden cardiac death (SCD) or sustained ventricular arrhythmias) without structural heart disease and with a family history (FH) of suspected SCD. Data collected between April 2021 and December 2023, included clinical features, diagnostic findings, and severe outcomes such as life-threatening arrhythmic events (sustained VT, SCD, ICD therapies), end-stage heart failure, or heart transplantation (Htx). Results Fourteen patients (12 probands, mean age 41 years, 57.1% male) were included. At presentation, 5/14 (35.7%) were asymptomatic, 8/14 (57.1%) had heart failure symptoms. ECG had a mean PR interval of 140 ms, with 5/14 (35.7%) <120 ms, and a mean QRS of 101.6 ms. None had low QRS voltage. DCM was diagnosed in 9/14 (64.3%), high-risk arrhythmogenic phenotype in 3/14 (21.4%), isolated left ventricular dilatation (iLVD) in 1/14 (7.1%), and familial screening with a negative phenotype in 1/14 (7.1%). In the DCM group, the mean LVEF was 27%, with mild late gadolinium enhancement in 4/9 (44.4%). Severe outcomes were only seen in the DCM group, such as Htx in 1/9 (11.1%) and SCD in 2/9 (22.2%), both with mild hypertrophy on histological evaluation. In the high-risk arrhythmogenic phenotype, the mean LVEF was 61.7%. Two patients exhibited sustained polymorphic VT during stress testing (ST), combined with a FH of DCM/SCD, and one had an aborted SCD. One was classified as iLVD, with LGE and non-sustained polymorphic VT during ST. Six distinct variants were identified, with p.Arg634Trp being the most common. Conclusion RBM20-related cardiomyopathy spans a broad phenotypic spectrum, from preserved ejection fraction with arrhythmias to end-stage heart failure and low incidence of LGE at cardiac resonance. Typical features include normal or short PR intervals and narrow QRS complexes. Expanding genotype-phenotype correlations is crucial to refining age-dependent penetrance, optimizing care for patients and their families.
No takes yet. Share an insight, caveat, or question.
Pagotti et al. (2025) conducted a cohort in RBM20-related cardiomyopathy (n=14). Pathogenic/likely pathogenic RBM20 variants was evaluated on Phenotypic profile and severe outcomes (life-threatening arrhythmic events, end-stage heart failure, or heart transplantation). Pathogenic RBM20 variants were associated with a broad phenotypic spectrum, including dilated cardiomyopathy in 64.3% of carriers, among whom 22.2% experienced sudden cardiac death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: